Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti‐CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases

BI 655064 is a humanized antagonistic anti‐cluster of differentiation (CD) 40 monoclonal antibody that selectively blocks the CD40‐CD40L interaction. The CD40‐CD40L pathway is a promising treatment target for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and lupus n...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwabe, Christian, Rosenstock, Bernd, Doan, Thi, Hamilton, Paul, Dunbar, P. Rod, Eleftheraki, Anastasia G., Joseph, David, Hilbert, James, Schoelch, Corinna, Padula, Steven J., Steffgen, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Pharmacokinetics/Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282763/
https://www.ncbi.nlm.nih.gov/pubmed/30113724
http://dx.doi.org/10.1002/jcph.1278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282763/
https://www.ncbi.nlm.nih.gov/pubmed/30113724
http://dx.doi.org/10.1002/jcph.1278

Ejemplares similares